drugset / Trial / NCT06441565
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this clinical trial is to evaluate the efficacy and safety of combining fruquintinib with hepatic artery infusion (HAI)-FOLFOX in the treatment of refractory colorectal cancer with liver metastasis.
Timeline
- Start
- 2024-05-24
- Primary completion
- 2025-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 2.8 g | Other |